Methyl gallate exhibits potent antitumor activities by inhibiting tumor infiltration of CD4+CD25+ regulatory T cells

Journal of Immunology

Volumn 185, Issue 11, 2010, Pages 6698-6705

  Heekyung, Lee ^a   Hyojung, Lee ^a   Youngjoo, Kwon ^a   Jun Ho, Lee ^a   Jinju, Kim ^b   Min Kyu, Shin ^a   Sung Hoon, Kim ^c   Hyunsu, Bae ^a  

^a Department of Physiology   (United States)

^b Department of Pharmacotherapy and Translational Research   (Pakistan)

^c Kyung Hee University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GALLIC ACID METHYL ESTER; GLUCOCORTICOID; MARKER; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER THERAPY; CD4+ CD25+ T LYMPHOCYTE; CELL COUNT; DRUG CYTOTOXICITY; DRUG EFFICACY; EFFECTOR CELL; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE MIGRATION; LYMPHOCYTE SUBPOPULATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN; SURVIVAL RATE; TUMOR GROWTH;

ANIMALS; ANTIGENS, CD4; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CELL MIGRATION INHIBITION; COCULTURE TECHNIQUES; DRUGS, CHINESE HERBAL; GALLIC ACID; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOMA, T-CELL; MALE; MICE; MICE, INBRED C57BL; MICE, NUDE; MICE, TRANSGENIC; PAEONIA; PLANT EXTRACTS; RANDOM ALLOCATION; T-LYMPHOCYTES, REGULATORY;

EID: 78650635612     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1001373     Document Type: Article

References (32)

1. Wei, S., I. Kryczek, and W. Zou. 2006. Regulatory T-cell compartmentalization and trafficking. Blood 108:426-431.
2. Bluestone, J. A., and A. K. Abbas. 2003. Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. 3:253-257.
3. Shevach, E. M. 2002. CD4+ CD25+ suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2:389-400.
4. Curiel, T. J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10:942-949.
5. Lizárraga, D., S. Touriño, F. J. Reyes-Zurita, T. M. de Kok, J. H. van Delft, L. M. Maas, J. J. Briedé, J. J. Centelles, J. L. Torres, and M. Cascante. 2008. Witch hazel (Hamamelis virginiana) fractions and the importance of gallate moieties: electron transfer capacities in their antitumoral properties. J. Agric. Food Chem. 56:11675-11682.
6. Da Silva, S. L., J. d. S. Chaar, and T. Yano. 2009. Chemotherapeutic potential of two gallic acid derivative compounds from leaves of Casearia sylvestris Sw (Flacourtiaceae). Eur. J. Pharmacol. 608:76-83.
7. Fiuza, S. M., C. Gomes, L. J. Teixeira, M. T. Girão da Cruz, M. N. Cordeiro, N. Milhazes, F. Borges, and M. P. Marques. 2004. Phenolic acid derivatives with potential anticancer properties: a structure-activity relationship study. 1. Methyl, propyl and octyl esters of caffeic and gallic acids. Bioorg. Med. Chem. 12:3581-3589.
8. +T cells in mice. Transpl. Immunol. 17:153-161.
9. Wei, S., I. Kryczek, R. P. Edwards, L. Zou, W. Szeliga, M. Banerjee, M. Cost, P. Cheng, A. Chang, B. Redman, et al. 2007. Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res. 67:7487-7494.
10. Ozao-Choy, J., G. Ma, J. Kao, G. X. Wang, M. Meseck, M. Sung, M. Schwartz, C. M. Divino, P. Y. Pan, and S. H. Chen. 2009. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 69:2514-2522.
11. Banissi, C., F. Ghiringhelli, L. Chen, and A. F. Carpentier. 2009. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol. Immunother. 58:1627-1634.
12. Lundqvist, A., H. Yokoyama, A. Smith, M. Berg, and R. Childs. 2009. Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells. Blood 113:6120-6127.
13. Matsushita, N., S. A. Pilon-Thomas, L. M. Martin, and A. I. Riker. 2008. Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J. Immunol. Methods 333:167-179.
14. Søndergaard, H., K. S. Frederiksen, P. Thygesen, E. D. Galsgaard, K. Skak, P. E. Kristjansen, N. Odum, and M. Kragh. 2007. Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors. Cancer Immunol. Immunother. 56:1417-1428.
15. Kilinc, M. O., K. S. Aulakh, R. E. Nair, S. A. Jones, P. Alard, M. M. Kosiewicz, and N. K. Egilmez. 2006. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors. J. Immunol. 177:6962-6973.
16. Hontsu, S., H. Yoneyama, S. Ueha, Y. Terashima, M. Kitabatake, A. Nakano, T. Ito, H. Kimura, and K. Matsushima. 2004. Visualization of naturally occurring Foxp3+ regulatory T cells in normal and tumor-bearing mice. Int. Immunopharmacol. 4:1785-1793.
17. Haribhai, D., W. Lin, L. M. Relland, N. Truong, C. B. Williams, and T. A. Chatila. 2007. Regulatory T cells dynamically control the primary immune response to foreign antigen. J. Immunol. 178:2961-2972.
18. Imai, H., M. Saio, K. Nonaka, T. Suwa, N. Umemura, G. F. Ouyang, J. Nakagawa, H. Tomita, S. Osada, Y. Sugiyama, et al. 2007. Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma. Cancer Sci. 98:416-423.
19. Mailloux, A. W., and M. R. Young. 2009. NK-dependent increases in CCL22 secretion selectively recruits regulatory T cells to the tumor microenvironment. J. Immunol. 182:2753-2765.
20. Sakaguchi, S., T. Yamaguchi, T. Nomura, and M. Ono. 2008. Regulatory T cells and immune tolerance. Cell 133:775-787.
21. Tan, M. C., P. S. Goedegebuure, B. A. Belt, B. Flaherty, N. Sankpal, W. E. Gillanders, T. J. Eberlein, C. S. Hsieh, and D. C. Linehan. 2009. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J. Immunol. 182:1746-1755.
22. Bui, J. D., R. Uppaluri, C. S. Hsieh, and R. D. Schreiber. 2006. Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. Cancer Res. 66:7301-7309.
23. Hiura, T., H. Kagamu, S. Miura, A. Ishida, H. Tanaka, J. Tanaka, F. Gejyo, and H. Yoshizawa. 2005. Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression. J. Immunol. 175:5058-5066.
24. Liu, Z., J. H. Kim, L. D. Falo, Jr., and Z. You. 2009. Tumor regulatory T cells potently abrogate antitumor immunity. J. Immunol. 182:6160-6167.
25. Hiraoka, N., K. Onozato, T. Kosuge, and S. Hirohashi. 2006. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin. Cancer Res. 12:5423-5434.
26. Olkhanud, P. B., D. Baatar, M. Bodogai, F. Hakim, R. Gress, R. L. Anderson, J. Deng, M. Xu, S. Briest, and A. Biragyn. 2009. Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. Cancer Res. 69:5996-6004.
27. Cho, J. S., J. V. Hsu, and S. L. Morrison. 2009. Localized expression of GITR-L in the tumor microenvironment promotes CD8+ T cell dependent anti-tumor immunity. Cancer Immunol. Immunother. 58:1057-1069.
28. Johnson, J. J., H. H. Bailey, and H. Mukhtar. 2010. Green tea polyphenols for prostate cancer chemoprevention: a translational perspective. Phytomedicine 17:3-13.
29. Adiseshaiah, P., D. J. Lindner, D. V. Kalvakolanu, and S. P. Reddy. 2007. FRA-1 proto-oncogene induces lung epithelial cell invasion and anchorage-independent growth in vitro, but is insufficient to promote tumor growth in vivo. Cancer Res. 67:6204-6211.
30. Kudo-Saito, C., J. Schlom, K. Camphausen, C. N. Coleman, and J. W. Hodge. 2005. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors. Clin. Cancer Res. 11:4533-4544.
31. Onizuka, S., I. Tawara, J. Shimizu, S. Sakaguchi, T. Fujita, and E. Nakayama. 1999. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 59:3128-3133.
32. Toda, A., and C. A. Piccirillo. 2006. Development and function of naturally occurring CD4+CD25+ regulatory T cells. J. Leukoc. Biol. 80:458-470.